Weight-loss injections are everywhere, but results still vary
GLP-1 medications have moved from a niche diabetes treatment to a mainstream weight-loss tool in a very short time. Surveys suggest roughly one in eight U.S. adults have tried drugs in this category, including Ozempic and similar medications.
But even with the same prescription, the experience can look different from person to person. Some people see steady changes in appetite and weight, while others feel like progress slows down, or doesn’t show up the way they expected.
What GLP-1 drugs do in the body
GLP-1 receptor agonists mimic a hormone involved in blood sugar control and appetite regulation. In simple terms, they can help people feel fuller sooner and reduce how much they want to eat, which is why they’re used in type 2 diabetes care and, increasingly, in obesity treatment.
That’s the headline benefit. The question researchers keep coming back to is why the response can still be uneven—especially when it comes to fat loss and body composition.
The study looked at eating behaviors before treatment
In a study involving 92 adults in Japan with type 2 diabetes, researchers tracked changes over time after participants were prescribed a GLP-1 medication. They monitored weight and body composition, alongside markers like blood sugar and cholesterol.
What made the research stand out was the behavioral angle: the team assessed three common eating patterns before and during treatment—external eating, emotional eating, and restrained eating.
External vs emotional vs restrained eating
The categories are widely used in behavioral nutrition research, and the distinctions are straightforward:
- External eating: eating triggered by cues like smell, appearance, or availability of food, rather than hunger.
- Emotional eating: eating in response to feelings like stress, sadness, or anxiety.
- Restrained eating: consciously restricting intake to control weight, often with periods of “holding back.”
These patterns can overlap, but the study treated them as separate signals that might predict who benefits most.
Who was least likely to lose fat on the jabs
The researchers reported that, over time, people whose overeating was driven mainly by emotional eating or restrained eating tended to lose less weight than those whose eating was more strongly influenced by external cues.
They also found that while many participants showed reduced emotional and external eating after about three months, emotional eating scores later drifted back toward baseline by the 12-month mark—suggesting the early appetite effect may not fully address the underlying drivers behind emotion-linked eating.
One of the authors suggested a possible reason: emotional eating may be shaped more by psychological factors that medication alone doesn’t directly change.
What this could mean (and what it doesn’t)
The takeaway isn’t that GLP-1 medications “don’t work” for people who emotionally eat. It’s that behavioral patterns might help explain why outcomes differ, and why some people may see less fat loss even while on the same type of drug.
The researchers also emphasized that these findings are preliminary and need validation in larger studies before they can be used to guide clinical decisions.
Why this matters as use keeps climbing
As more people try weight-loss jabs, expectations are rising with them. And with uptake now widespread—again, about 12% of U.S. adults have tried GLP-1 drugs, according to a KFF survey—understanding who benefits most (and why) matters for patients, clinicians, and health systems alike.
If future research confirms these links, a simple check-in on eating behaviors could become one more tool for setting realistic expectations and pairing medication with the right kind of support.
Featured Image Credit: Getty Images/Tatsiana Volkava
